Drug Approval | January 19, 2024
Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
Jublia (Efinaconazole) topical solution, 10% had annual sales of $292 million in the United States according to IQVIA data (IQVIA MAT May 2022).
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)